CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Eloxx Pharmaceuticals, Inc. (ELOX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Eloxx Pharmaceuticals, Inc. (ELOX)

Biological Products, (No Diagnostic Substances) · market cap $64M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-17 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Eloxx Pharmaceuticals (ELOX) is a clinical-stage company in our data with a Phase 2 lead, Exaluren, in X-linked Alport Syndrome. It also lists ELX-02 and Ivacaftor in Phase 2 for Cystic Fibrosis. At a ~$53M market cap against $62.0M of cash, the stock trades below reported cash, and the next major catalyst in our calendar is an estimated Exaluren Phase 2 event on 2027-06-30.
The catalyst path
  • 2026-11-17 (est.)Earningsimp 5/10
  • 2027-06-30 (est.)Phase 2 · Exalurenimp 7/10
Pipeline
AssetPhaseIndication
IvacaftorPhase 2Cystic Fibrosis
ELX-02Phase 2Cystic Fibrosis
ExalurenPhase 2Alport Syndrome, X-Linked

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ELOX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.